

17 February 2026

**Fusion Antibodies plc  
("Fusion" or the "Company")**

**Director/PDMR Shareholding**

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified that Simon Douglas, Non-Executive Chair of Fusion, has today transferred 200,000 ordinary shares of 4 pence each in the Company ("Ordinary Shares") to his daughters (the "Transfer"). Following the Transfer, Simon Douglas directly holds 861,062 Ordinary Shares, representing approximately 0.69 per cent. of the Company's issued share capital.

Details of the director dealing is set out in the table at the end of this announcement, which has been provided in accordance with the requirements of the UK Market Abuse Regulation.

**Enquiries:**

**Fusion Antibodies plc**

Adrian Kinkaid, Chief Executive Officer  
Stephen Smyth, Chief Financial Officer

[www.fusionantibodies.com](http://www.fusionantibodies.com)  
Via Walbrook PR

**Fusion Antibodies interactive investor hub**

<https://investorhub.fusionantibodies.com/>

**Allenby Capital Limited**

James Reeve/Vivek Bhardwaj (Corporate Finance)  
Tony Quirke/Joscelin Pinnington (Sales and Corporate  
Broking)

Tel: +44 (0) 20 3328 5656

**Shard Capital Partners LLP**

Damon Heath (Joint Broker)

Tel: +44 (0) 207 186 9952

**Walbrook PR**

Anna Dunphy

Tel: +44 (0)20 7933 8780 or [fusion@walbrookpr.com](mailto:fusion@walbrookpr.com)

Mob: +44 (0)7876 741

001

**About Fusion Antibodies plc**

Fusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.

The range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRx<sup>TM</sup> platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.

At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class discovery (OptiMAL<sup>®</sup> and OptiPhage<sup>TM</sup>), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic.

Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our Integrated Therapeutic Antibody Services ("ITA") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to

as far as a stable cell line. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.

Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at 253 billion in 2024 and forecast to reach nearly 500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than 5 billion in 2023.

While therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.

## **Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>					
a)	Name	Simon Douglas				
<b>2</b>	<b>Reason for the notification</b>					
a)	Position/status	Non-Executive Chairman				
b)	Initial notification /Amendment	Initial notification				
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a)	Name	Fusion Antibodies plc				
b)	LEI	213800KBAYRC9V0Q9V39				
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a)	Description of the financial instrument, type of instrument	ordinary shares of 4p each in Fusion Antibodies plc				
	Identification code	Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16				
b)	Nature of the transaction	Transfer of Ordinary Shares				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Nil</td> <td>200,000</td> </tr> </table>	Price(s)	Volume(s)	Nil	200,000
Price(s)	Volume(s)					
Nil	200,000					
d)	Aggregated information - Aggregated volume - Price	- see above - see above				
e)	Date of the transaction	17 February 2026				
f)	Place of the transaction	Outside a trading venue				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSFSFFWEMSELE